ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

telisotuzumab adizutecan

Also written as “Telisotuzumab Adizutecan”, “RC148 plus Telisotuzumab adizutecan” and “ABBV-400”.

In AbbVie’s pipeline, c-Met. Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular, led by 2 companies.

Drug pageTelisotuzumab adizutecan: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 27, 202518 company-led studies, 18 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only1717 open or runningphase 3since May 27, 2025Aug 30, 2021Dec 2026phase 2 · NCT06107413
RemeGen11 open or runningphase 2since Oct 12, 2026Oct 12, 2026Jul 2028phase 2 · NCT07895355
  • Named in AbbVie’s own pipeline as Temab-A (ABBV-400), phase 3, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of RemeGen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 29, 2024Named telisotuzumab adizutecanINNProposed as its International Nonproprietary Name in WHO's List 130 · before, ABBV-400
  2. Oct 12, 2026First study: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyFirst studyNCT07895355 · 412 planned · China

Ahead

  1. Jul 2028Primary completion: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNCT07895355

TargetBeta

“c-Met”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

The one study RemeGen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07895355Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy · China2Not yet recruitingJul 2028412

How it is read

Names in the registry

  • “Telisotuzumab Adizutecan”, 12 entries
  • “RC148 plus Telisotuzumab adizutecan”, 4 entries
  • “ABBV-400”, 3 entries
  • “Telisotuzumab adizutecan”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.